Secalciferol
≥98%
- Product Code: 57226
CAS:
55721-11-4
| Molecular Weight: | 416.64 g./mol | Molecular Formula: | C₂₇H₄₄O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
Secalciferol is primarily used in the treatment of conditions related to calcium and phosphate metabolism. It is effective in managing hypocalcemia in patients with chronic kidney disease, particularly those on dialysis, as it helps regulate the levels of calcium and phosphate in the blood. Additionally, it is utilized to treat secondary hyperparathyroidism, a condition often associated with kidney failure, by reducing the production of parathyroid hormone. Secalciferol also supports bone health by promoting calcium absorption in the intestines and maintaining proper bone mineralization. Its application is crucial in preventing bone disorders such as osteomalacia and osteoporosis in patients with impaired kidney function.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | colorless to white powder or crystals |
| PURITY | 97.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | ฿76,360.00 |
+
-
|
Secalciferol
Secalciferol is primarily used in the treatment of conditions related to calcium and phosphate metabolism. It is effective in managing hypocalcemia in patients with chronic kidney disease, particularly those on dialysis, as it helps regulate the levels of calcium and phosphate in the blood. Additionally, it is utilized to treat secondary hyperparathyroidism, a condition often associated with kidney failure, by reducing the production of parathyroid hormone. Secalciferol also supports bone health by promoting calcium absorption in the intestines and maintaining proper bone mineralization. Its application is crucial in preventing bone disorders such as osteomalacia and osteoporosis in patients with impaired kidney function.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :